Trials / Completed
CompletedNCT00425256
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Palatin Technologies, Inc · Industry
- Sex
- Female
- Age
- 21 Years – 70 Years
- Healthy volunteers
- —
Summary
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bremelanotide |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2007-01-22
- Last updated
- 2011-02-23
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00425256. Inclusion in this directory is not an endorsement.